Entering text into the input field will update the search result below

RXi Pharma announces business strategy to focus on immuno-oncology programs to accelerate growth

  • RXi Pharmaceuticals (RXII) has outlined its 2018 business strategy at the Biotech Showcase Conference.
  • RXi will focus development initiatives on novel immuno-oncology therapeutics using its proprietary sd-rxRNA platform, with a near term focus on Adoptive Cell Transfer. This will reduce quarterly burn-rate for 2018.
  • The Company plans to accelerate the development of RXI-762 and RXI-804, sd-rxRNA compounds.
  • Expanding research resources, internal development efforts and external collaborations with various existing cell-based approaches.
  • Developing immuno-oncology targets beyond checkpoint inhibition, i.e. cell differentiation.
  • RXi intends to partner/out-license both its Dermatology and Ophthalmology Franchises. These transactions will provide non-dilutive funding for the Company's focused development path in Immuno-oncology.

Recommended For You

More Trending News

About PHIO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PHIO--
Phio Pharmaceuticals Corp.